Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD. METHODS: This was an international, multicenter, double-blind, randomized, parallel-group study. Subjects had mild to moderate probable AD (Mini-Mental State Examination score 13-25), were aged 50-90 years, and were taking donepezil 10 mg daily for > or 3 months prior to screening. Entry low-density lipoprotein cholesterol levels (LDL-C) were > 95 and < 195 mg/dL. Patients were randomized to atorvastatin 80 mg/day or placebo for 72 weeks followed by a double-blind, 8-week atorvastatin withdrawal phase. Coprimary endpoints were changes in cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog]) and global function (Alzheimer's Disease Cooperative Study Clinical Global Impression of Change [ADCS-CGIC]) at 72 weeks. RESULTS: A total of 640 patients were randomized in the study. There were no significant differences in the coprimary endpoints of ADAS-cog or ADCS-CGIC or the secondary endpoints. Atorvastatin was generally well-tolerated. CONCLUSIONS: In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks. This treatment was generally well-tolerated without unexpected adverse events. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that intensive lipid lowering with atorvastatin 80 mg/day in patients with mild to moderate probable Alzheimer disease (aged 50-90), taking donepezil, with low-density lipoprotein cholesterol levels between 95 and 195 mg/dL over 72 weeks does not benefit cognition (as measured by Alzheimer's Disease Assessment Scale-Cognitive Subscale) (p = 0.26) or global function (as measured by Alzheimer's Disease Cooperative Study Clinical Global Impression of Change) (p = 0.73) compared with placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies have suggested a beneficial effect of aspirin on cognition,465,466 although this was not confirmed in others.467,468”
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
A nonparametric method for automatic correction of intensity nonuniformity in MRI data
Sled, J. G., Zijdenbos, A. P., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.668698 · Cited by 4,731
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Research works printed but not linked: 3
- Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:63–70.
- Austen B, Frears E, Davies H. Cholesterol upregulates production of A[beta] 1-40 and 1-42 in transfected cells. Neurobiol Aging 2000;21:254.
- Hoglund K, Wallin A, Blennow K. Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:87–92.
Cited by
Items 401–443 of 443
1. Prevention of Dementia by the Control of Non-genetic Risk Factors
Sato, N. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.1815
The Current Status of Alzheimer's Disease Treatment
Lanctôt, K. L., Kircanski, I., Chau, S. A., & Herrmann, N. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-5 · Cited by 1
Lorette, A. (2012)
STATINS IN PREVENTION OF POSTOPERATIVE COGNITIVE DYSFUNCTION IN PATIENTS AFTER CARDIAC SURGERY
Валерьевна, М. О., Trubnikova, O. A., & Барбараш, О. Л. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-95-106
LYSOSOMAL STORAGE DISEASES: DIFFICULTIES IN DIFFERINTIAL DIAGNOSIS
POMYTKINA, T. Y., & DAVYDOVA, A. Y. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-129-133
TRENDS IN GASTRIC CANCER INCIDENCE AMONG THE POPULATION OF OMSK REGION
Ширлина, Н. Г., Stasenko, V. L., Shirinsky, V. A., SHIRINSKAYA, N. A., & Обухова, Т. М. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-66-71
Борзалиевна, П. Т., Gruzdeva, O. V., & Барбараш, О. Л. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-28-41
Dementia and Mild Cognitive Impairment: Epidemiologic Research of Risk Factors
George, K. M. (2019) · University of Minnesota Digital Conservancy (University of Minnesota)
A study of the global effects of Apolipoprotein E using lipidomics
Hawksworth, J. I. (2019) · ORCA Online Research @Cardiff (Cardiff University)
Chen, Y. S. (2018) · theses.fr (ABES) · doi:10.70675/add1c75dzdb73z46dezac5fza0b3b19367da · Cited by 1
Strategies for patient therapy with chronic brain ischemia
Kurushina, O. V., Барулин, А. Е., & Vorobyova, Y. S. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-21-86-93
Arterial Calcification and Cerebral Disease: Stroke and Dementia
Jashari, F., Wester, P. O., & Henein, M. Y. (2021) · Springer eBooks · doi:10.1007/978-3-030-81515-8_12
Patel, A. V., & Libman, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_37 · Cited by 1
Deardorff, W. J., & Grossberg, G. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-74604-3_9
Current awareness in geriatric psychiatry
(2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2398
Supportive Pharmacological Treatment
Otoni, K. M., MORMINO, K. B. N. T., dos Santos, S. L. F., & Pereira, M. L. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-94383-7_6
Involvement of cholesterol and β-amyloid in the initiation and progression of Alzheimer’s disease
Aguayo, L. G., Roa, J., Burgos, C. F., & González-Sanmiguel, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00039-0 · Cited by 1
Current Treatments for Alzheimer’s Disease
Sano, M., & Neugroschil, J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0057
An, G.-M., Jung, T., Yun, S.-S., Choi, J., Nam, M. J., & Han, K. (2023) · Applied Sciences · doi:10.3390/app132111656
Combination therapies delay cognitive decline over 10 years in Alzheimer’s NACC participantsPreprint
Shang, Y., Torrandell‐Haro, G., Vitali, F., & Brinton, R. D. (2024) · medRxiv · doi:10.1101/2024.01.31.24301055
Outland, E. H., Xin, Y., Dickson, A. L., Mundo, S., Tao, R., Zhong, X. Y., Karakoc, G., Serley, S., Jiang, L., Cox, N. J., et al. (2025) · medRxiv · doi:10.1101/2025.03.07.25323588 · Cited by 1
Target the Heart: A New Axis of Alzheimer’s Disease Prevention
Heller, L. I., Lowe, A. S., Hernández, T. D. R., Gore, S. V., Chatterjee, M., & Créton, R. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2020010
“These results are consistent with a randomized controlled trial of atorvastatin in mild-to-moderate AD, where the treatment was ineffective in improving cognition on the same scale [70].”
Alzheimer disease and non-genetic risk factors
Sato, N. (2012) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.49.311
Petek, B., Häbel, H., Xu, H., Villa‐Lopez, M., Kalar, I., Hoang, M. T., Maioli, S., Pereira, J. B., Mostafaei, S., Winblad, B., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24873040
Candeias, E. M. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Ferré‐González, L., Peña‐Bautista, C., Álvarez‐Sánchez, L., Peretó, M., García, L., Raga, L., Roca, M. I., Baquero, M., & Cháfer‐Pericás, C. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.025
Neuroimaging markers in clinical trials for pre-dementia stages of Alzheimer's disease
Cavedo, E. (2015) · theses.fr (ABES) · doi:10.70675/04f8d65dz4c15z4cebzbb7bz08189dec5d06 · Cited by 1
ANIMAL Antidépresseurs, neuroinflammation et maladie d'alzheimer
Gosselin, T. (2016) · theses.fr (ABES) · doi:10.70675/11bcd9acz165fz4338zb013z5a469c5aed72
Vieillissement cognitif réussi : système nerveux autonome, sommeil et interactions sociales
Martin, M. S. (2014) · theses.fr (ABES) · doi:10.70675/35437193z315bz403cza20dz5c3eb6890517 · Cited by 1
Ceyzériat, K. (2017) · theses.fr (ABES) · doi:10.70675/ab03c3a1z5d4cz4adfz8b9dzf5a6b4dae610 · Cited by 2
Enette, L. (2019) · theses.fr (ABES) · doi:10.70675/1ad1a02ez8eebz4234z9bdfzf1e991390f85
Vautheny, A. (2019) · theses.fr (ABES) · doi:10.70675/1812d71aze8d9z48d6z87d1z5a23a4e81953
Meddeb, W. (2018) · theses.fr (ABES) · doi:10.70675/c3b5210bzc7adz464bz9d5fz0dcc915f69c8 · Cited by 1
Bergeron, S. (2018) · theses.fr (ABES) · doi:10.70675/36a54739zd120z440bzac6aze1ff3180f9f1 · Cited by 1
Exploring the role of statin interventions on cognitive function by Mendelian randomization study
He, Y., Yang, H., Pan, T., Wang, F., Zeng, X., Huang, J., & Yang, Q. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261440863
Wu, Y., Di, Y., Wang, H. W., Wang, L., Zhang, J., Zhang, Y., & Lyu, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103216
THERAPY FOR ALZHEIMER’S DISEASE - FOCUS ON LECANEMAB
Jońca, M., Majchrowicz, G., Kurys, N., Piekarska, W., Litke, S., & Gołacka, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5795
Imbimbo, B. P., Pomara, N., Pini, L., & Frederiksen, K. S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119943
Ning, X., Xiao, Y., Wang, N., Jiao, X., Li, X., Zhang, Y., & Zhao, Q. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261491977
Enzyme−Targeted Therapeutics for Neurological Disorders
Massignan, L., Lokesh, K., Ziadat, S., Uehling, D., Weaver, D. F., & Reed, M. A. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01274
Metadata
- Authors
- Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., & Breazna, A.
- Affiliations
- San Francisco General Hospital (US)
- From the Division of Neurology (H.H.F.), University of British Columbia, UBCH Clinic for Alzheimer's Disease and Related Disorders, Vancouver, Canada; Department of Neurology (R.S.D.), Baylor College of Medicine, Houston, TX; Aging Research Center (M.K.), Karolinska Institutet, Stockholm, Sweden; Ralph & Muriel Roberts Laboratory For Neurodegenerative Research (D.L.S.), Sun Health Research Institute, Sun City, AZ; San Francisco General Hospital (D.D.W.), San Francisco, CA; RICE (The Research...
- Venue
- Neurology
- Published
- 2010-03-23
- Volume
- 74
- Issue
- 12
- Pages
- 956-964
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2030025114
- Cited by
- 438
- References
- 38
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 14 · 2023: 12 · 2022: 10 · 2021: 18 · 2020: 27 · 2019: 42 · 2018: 16 · 2017: 26 · 2016: 34 · 2015: 26 · 2014: 33 · 2013: 28 · 2012: 49
- FWCI
- 32.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Pfizer
- IXICO
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- atorvastatin, Alzheimer's disease, statins, lipid lowering, donepezil, cognitive function, global function, LDL cholesterol, drug safety and efficacy
- MeSH terms
- Atorvastatin, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Heptanoic Acids, Hippocampus, Humans, Cholesterol, LDL, Magnetic Resonance Imaging, Male, Middle Aged, Organ Size, Pyrroles, Cholinergic Antagonists, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.